Naratriptan (BioDeep_00000006604)

 

Secondary id: BioDeep_00001868203

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


1H-Indole-5-ethanesulfonamide, N-methyl-3-(1-methyl-4-piperidinyl)-, monohydrochloride

化学式: C17H25N3O2S (335.1667)
中文名称: 那拉曲坦
谱图信息: 最多检出来源 Mus musculus(blood) 3.4%

分子结构信息

SMILES: CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C
InChI: InChI=1S/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H3

描述信息

Naratriptan is only found in individuals that have used or taken this drug. It is a triptan drug used for the treatment of migraine headaches. It is a selective 5-hydroxytryptamine1 receptor subtype agonist.Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism.
N - Nervous system > N02 - Analgesics > N02C - Antimigraine preparations > N02CC - Selective serotonin (5ht1) agonists
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists
C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist
D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents

同义名列表

19 个代谢物同义名

1H-Indole-5-ethanesulfonamide, N-methyl-3-(1-methyl-4-piperidinyl)-, monohydrochloride; N-Methyl-3-(1-methyl-4-piperidyl)indole-5-ethanesulfonamide monohydrochloride; N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethane-1-sulfonamide; N-Methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulphonamide; N-Methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide; N-Methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulphonamide; N-Methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide; N-Methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide; GlaxoSmithKline brand OF naratriptan hydrochloride; Glaxo wellcome brand OF naratriptan hydrochloride; Schwarz brand OF naratriptan hydrochloride; Faes brand OF naratriptan hydrochloride; Naratriptan Hydrochloride; Naratriptanum; naratriptan; Naramig; Colatan; Amerge; Naratriptan



数据库引用编号

15 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 6 ABCB1, AR, CACNA1A, DUSP1, GRM5, S100A12
Peripheral membrane protein 1 S100A12
Nucleus 6 AR, ATF3, CACNA1A, DUSP1, FOS, S100A12
cytosol 3 AR, FOS, S100A12
dendrite 5 GRM5, HTR1A, HTR1D, HTR1F, HTR2C
nucleoplasm 3 AR, ATF3, FOS
RNA polymerase II transcription regulator complex 2 ATF3, FOS
Cell membrane 10 ABCB1, CACNA1A, GRM5, HTR1A, HTR1D, HTR1F, HTR2C, HTR3A, S100A12, SLC47A1
Cleavage furrow 1 HTR3A
Multi-pass membrane protein 10 ABCB1, CACNA1A, CACNA1I, GRM5, HTR1A, HTR1D, HTR1F, HTR2C, HTR3A, SLC47A1
Synapse 7 CACNA1A, HTR1A, HTR1D, HTR1F, HTR2C, HTR3A, TAC1
cell surface 1 ABCB1
dendritic shaft 1 GRM5
glutamatergic synapse 1 GRM5
neuronal cell body 3 CACNA1A, GRM5, TAC1
postsynapse 2 GRM5, HTR3A
plasma membrane 13 ABCB1, AR, CACNA1A, CACNA1I, GRM5, HTR1A, HTR1D, HTR1F, HTR2C, HTR3A, ICAM3, S100A12, SLC47A1
Membrane 8 ABCB1, AR, CACNA1A, CACNA1I, GRM5, HTR3A, ICAM3, SLC47A1
apical plasma membrane 2 ABCB1, SLC47A1
axon 1 TAC1
basolateral plasma membrane 1 SLC47A1
extracellular exosome 3 ABCB1, ARSF, ICAM3
endoplasmic reticulum 1 FOS
extracellular space 2 IL6, TAC1
Schaffer collateral - CA1 synapse 1 GRM5
protein-containing complex 1 AR
Single-pass type I membrane protein 1 ICAM3
Secreted 4 ADCYAP1, ARSF, IL6, S100A12
extracellular region 4 ADCYAP1, IL6, S100A12, TAC1
dendritic spine 1 GRM5
perikaryon 1 ADCYAP1
nucleolus 1 ATF3
postsynaptic membrane 1 HTR3A
Apical cell membrane 2 ABCB1, SLC47A1
Cytoplasm, cytoskeleton 1 S100A12
nuclear speck 1 AR
Postsynaptic cell membrane 1 HTR3A
neuron projection 2 ADCYAP1, HTR3A
chromatin 3 AR, ATF3, FOS
cell projection 1 CACNA1A
cytoskeleton 1 S100A12
serotonin-activated cation-selective channel complex 1 HTR3A
transmembrane transporter complex 1 HTR3A
monoatomic ion channel complex 1 CACNA1A
Cell projection, dendrite 1 HTR1A
secretory granule lumen 1 S100A12
endoplasmic reticulum lumen 2 ARSF, IL6
nuclear matrix 1 FOS
voltage-gated calcium channel complex 2 CACNA1A, CACNA1I
postsynaptic density membrane 1 GRM5
protein-DNA complex 1 FOS
external side of apical plasma membrane 1 ABCB1
astrocyte projection 1 GRM5
transcription factor AP-1 complex 1 FOS
interleukin-6 receptor complex 1 IL6
CHOP-ATF3 complex 1 ATF3
G protein-coupled serotonin receptor complex 1 HTR2C


文献列表

  • Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
  • Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
  • Irene Wood, Mónica Pickholz. Naratriptan aggregation in lipid bilayers: perspectives from molecular dynamics simulations. Journal of molecular modeling. 2016 Sep; 22(9):221. doi: 10.1007/s00894-016-3096-8. [PMID: 27558798]
  • Kentaro Tokuoka, Risa Takayanagi, Yuji Suzuki, Masayuki Watanabe, Yasuhisa Kitagawa, Yasuhiko Yamada. Theory-based analysis of clinical efficacy of triptans using receptor occupancy. The journal of headache and pain. 2014 Dec; 15(?):85. doi: 10.1186/1129-2377-15-85. [PMID: 25488888]
  • Irene Wood, Mónica Pickholz. Triptan partition in model membranes. Journal of molecular modeling. 2014 Oct; 20(10):2463. doi: 10.1007/s00894-014-2463-6. [PMID: 25249023]
  • Daxesh P Patel, Primal Sharma, Mallika Sanyal, Puran Singhal, Pranav S Shrivastav. Challenges in the simultaneous quantitation of sumatriptan and naproxen in human plasma: application to a bioequivalence study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2012 Aug; 902(?):122-31. doi: 10.1016/j.jchromb.2012.06.041. [PMID: 22818944]
  • Venkata Suresh Ponnuru, B R Challa, Ramarao Nadendla. Quantitative analysis of eletriptan in human plasma by HPLC-MS/MS and its application to pharmacokinetic study. Analytical and bioanalytical chemistry. 2011 Nov; 401(8):2539-48. doi: 10.1007/s00216-011-5341-4. [PMID: 21892641]
  • Manish Yadav, Chirag Patel, Mahendra Patel, Tulsidas Mishra, Girin A Baxi, Puran Singhal, Pranav S Shrivastav. Development and validation of a sensitive and rapid method to determine naratriptan in human plasma by LC-ESI-MS-MS: application to a bioequivalence study. Journal of chromatographic science. 2011 Feb; 49(2):101-7. doi: 10.1093/chrsci/49.2.101. [PMID: 21223633]
  • Necla Calışkan, Eda Sögüt, Cafer Saka, Yavuz Yardım, Zuhre Sentürk. The natural diatomite from caldiran-van (Turkey): electroanalytical application to antimigraine compound naratriptan at modified carbon paste electrode. Combinatorial chemistry & high throughput screening. 2010 Sep; 13(8):703-11. doi: 10.2174/138620710791920356. [PMID: 20426734]
  • Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance. Journal of medicinal chemistry. 2009 Aug; 52(15):4844-52. doi: 10.1021/jm900403j. [PMID: 19445515]
  • Pavel Ptácek, Josef Klíma, Jan Macek. Optimized method for the determination of itopride in human plasma by high-performance liquid chromatography with fluorimetric detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2009 Mar; 877(8-9):842-6. doi: 10.1016/j.jchromb.2009.02.023. [PMID: 19246254]
  • R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1385-405. doi: 10.1124/dmd.108.020479. [PMID: 18426954]
  • Peer Tfelt-Hansen. Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. a comment. The journal of headache and pain. 2007 Oct; 8(5):273-6. doi: 10.1007/s10194-007-0411-x. [PMID: 17955173]
  • Miguel J A Láinez. Rizatriptan in the treatment of migraine. Neuropsychiatric disease and treatment. 2006 Sep; 2(3):247-59. doi: 10.2147/nedt.2006.2.3.247. [PMID: 19412472]
  • Ihsan Ergün, M Cenk Akbostanci, Başol Canbakan, Bilge Koçer, Arzu Ensari, Gökhan Nergizoglu, Kenan Keven. Minimal change nephrotic syndrome with stiff-person syndrome: is there a link?. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2005 Jul; 46(1):e11-4. doi: 10.1053/j.ajkd.2005.03.009. [PMID: 15983949]
  • Markus Färkkilä, Mikko Kallela. Eletriptan review. Expert opinion on pharmacotherapy. 2005 Apr; 6(4):625-30. doi: 10.1517/14656566.6.4.625. [PMID: 15934888]
  • David B Wainscott, Joseph H Krushinski, James E Audia, John M Schaus, John M Zgombick, Virginia L Lucaites, David L Nelson. [3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties. Naunyn-Schmiedeberg's archives of pharmacology. 2005 Mar; 371(3):169-77. doi: 10.1007/s00210-005-1035-9. [PMID: 15900510]
  • Geoffrey A Lambert. Preclinical neuropharmacology of naratriptan. CNS drug reviews. 2005; 11(3):289-316. doi: 10.1111/j.1527-3458.2005.tb00048.x. [PMID: 16389295]
  • David C Evans, Desmond O'Connor, Brian G Lake, Raymond Evers, Christopher Allen, Richard Hargreaves. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug metabolism and disposition: the biological fate of chemicals. 2003 Jul; 31(7):861-9. doi: 10.1124/dmd.31.7.861. [PMID: 12814962]
  • K Zimmermann, W P Reeh, B Averbeck. S+ -flurbiprofen but not 5-HT1 agonists suppress basal and stimulated CGRP and PGE2 release from isolated rat dura mater. Pain. 2003 Jun; 103(3):313-320. doi: 10.1016/s0304-3959(02)00459-1. [PMID: 12791437]
  • Carlos M Villalón, David Centurión, Luis Felipe Valdivia, Peter de Vries, Pramod R Saxena. Migraine: pathophysiology, pharmacology, treatment and future trends. Current vascular pharmacology. 2003 Mar; 1(1):71-84. doi: 10.2174/1570161033386826. [PMID: 15320857]
  • C M Villalón, D Centurión, L F Valdivia, P De Vries, P R Saxena. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proceedings of the Western Pharmacology Society. 2002; 45(?):199-210. doi: . [PMID: 12434581]
  • N Einer-Jensen, L Larsen, S Deprez, E Starns, S Schwartz. Intranasal absorption of sumatriptan and naratriptan: no evidence of local transfer from the nasal cavities to the brain arterial blood in male rats. Biopharmaceutics & drug disposition. 2001 Jul; 22(5):213-9. doi: 10.1002/bdd.281. [PMID: 11745923]
  • M L Christensen, S K Eades, E Fuseau, R D Kempsford, S J Phelps, L J Hak. Pharmacokinetics of naratriptan in adolescent subjects with a history of migraine. Journal of clinical pharmacology. 2001 Feb; 41(2):170-5. doi: 10.1177/00912700122009980. [PMID: 11210397]
  • S S Jhee, T Shiovitz, A W Crawford, N R Cutler. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clinical pharmacokinetics. 2001; 40(3):189-205. doi: 10.2165/00003088-200140030-00004. [PMID: 11327198]
  • D Deleu, Y Hanssens. Current and emerging second-generation triptans in acute migraine therapy: a comparative review. Journal of clinical pharmacology. 2000 Jul; 40(7):687-700. doi: 10.1177/00912700022009431. [PMID: 10883409]
  • K Vishwanathan, M G Bartlett, J T Stewart. Determination of antimigraine compounds rizatriptan, zolmitriptan, naratriptan and sumatriptan in human serum by liquid chromatography/electrospray tandem mass spectrometry. Rapid communications in mass spectrometry : RCM. 2000; 14(3):168-72. doi: 10.1002/(sici)1097-0231(20000215)14:3<168::aid-rcm861>3.0.co;2-9. [PMID: 10637423]
  • A MaassenVanDenBrink, M Reekers, W A Bax, M D Ferrari, P R Saxena. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation. 1998 Jul; 98(1):25-30. doi: 10.1161/01.cir.98.1.25. [PMID: 9665056]
  • H E Connor, W Feniuk, D T Beattie, P C North, A W Oxford, D A Saynor, P P Humphrey. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia : an international journal of headache. 1997 May; 17(3):145-52. doi: 10.1046/j.1468-2982.1997.1703145.x. [PMID: 9170336]
  • B D Duléry, M A Petty, J Schoun, M David, N D Huebert. A method using a liquid chromatographic-electrospray-mass spectrometric assay for the determination of antimigraine compounds: preliminary pharmacokinetics of MDL 74,721, sumatriptan and naratriptan, in rabbit. Journal of pharmaceutical and biomedical analysis. 1997 Apr; 15(7):1009-20. doi: 10.1016/s0731-7085(96)01955-3. [PMID: 9160269]